secwatch.observer — SEC 8-K summary
======================================

Issuer:     RenovoRx, Inc. (RNXT)
CIK:        0001574094
Form:       8-K
Filed at:   2024-02-23T23:59:59+00:00
Accession:  0001493152-24-007693
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

RenovoRx receives Nasdaq delisting notice for equity deficiency; COO resigns, new Chief Clinical Officer appointed
--------------------------------------------------------------------------------

- Nasdaq notified RenovoRx on Feb 21, 2024 that it failed minimum stockholders' equity of $2.5M; delisting proceedings to begin unless hearing requested.
- Company plans to request hearing, which will stay delisting pending panel decision; previously raised ~$6.1M in private placement to bolster equity.
- Chief Operating Officer Angela Gill Nelms resigned effective March 1, 2024 for personal reasons, no disagreement with company.
- Board appointed Leesa Gentry, current SVP Clinical Operations, as Chief Clinical Officer effective March 1, 2024, assuming clinical/regulatory duties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224007693/0001493152-24-007693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574094/000149315224007693/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-007693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer